Datta Pradip, Dasgupta Amitava
Bayer HealthCare, Diagnostics Division, Tarrytown, New York, USA.
J Clin Lab Anal. 2007;21(3):188-92. doi: 10.1002/jcla.20176.
A recent report indicates that hydroxyzine and its active metabolite cetirizine interfere with the particle-enhanced turbidimetric inhibition immunoassay (PENTINA) carbamazepine assay. We studied potential interference of hydroxyzine and cetirizine with the turbidimetric carbamazepine immunoassay on ADVIA 1650 and ADVIA 2400 (Bayer Diagnostics, Tarrytown, NY) analyzers. Aliquots of drug-free serum pools were supplemented with various concentrations of hydroxyzine and cetirizine representing therapeutic, moderate toxic, as well as very toxic concentrations. These samples were assayed by the turbidimetric carbamazepine immunoassay on two analyzers. To study the interference in presence of the analyte, aliquots of a serum pool prepared from patients receiving carbamazepine were further supplemented with various amounts of hydroxyzine and or cetirizine and apparent carbamazepine concentrations were measured again in order to compare with the value of original pool. No apparent carbamazepine concentration was observed when aliquots of drug-free serum were supplemented with hydroxyzine or cetirizine. Moreover, in the carbamazepine pool, the original carbamazepine concentration compared well when aliquots of this serum pool were further supplemented with hydroxyzine or cetirizine. We conclude that the turbidimetric carbamazepine immunoassay is free from interference of hydroxyzine and cetirizine.
最近的一份报告表明，羟嗪及其活性代谢物西替利嗪会干扰颗粒增强比浊抑制免疫测定法（PENTINA）的卡马西平检测。我们研究了羟嗪和西替利嗪对ADVIA 1650和ADVIA 2400（拜耳诊断公司，纽约塔里敦）分析仪上比浊法卡马西平免疫测定的潜在干扰。将无药血清池的等分试样补充不同浓度的羟嗪和西替利嗪，这些浓度分别代表治疗浓度、中度中毒浓度以及极毒浓度。这些样品在两台分析仪上通过比浊法卡马西平免疫测定进行检测。为了研究在存在分析物的情况下的干扰，将接受卡马西平治疗的患者制备的血清池的等分试样进一步补充不同量的羟嗪和/或西替利嗪，并再次测量表观卡马西平浓度，以便与原始血清池的值进行比较。当向无药血清的等分试样中补充羟嗪或西替利嗪时，未观察到明显的卡马西平浓度。此外，在卡马西平血清池中，当向该血清池的等分试样中进一步补充羟嗪或西替利嗪时，原始卡马西平浓度比较吻合。我们得出结论，比浊法卡马西平免疫测定不受羟嗪和西替利嗪的干扰。
